Strategic Advisory Board

The Strategic Advisory Board (SAB) is composed of leaders in health care, with expert knowledge on the impact of medication management on costs and outcomes, relevant healthcare legislation and policy, reimbursement models, and patient advocacy. The SAB provides thought leadership and high-level guidance and insight on areas of strategic growth to Cureatr.

Meet the Board Members


Jim Jorgenson

CEO and Board Chair, Visante, Inc. and Visante Limited
Jim Jorgenson

Jim Jorgenson is CEO of Visante where he leads national and international programs for medicines management improvement in the US, UK and Canada. His more than 30-year career includes pharmacy oversight of very large health systems and their network associations as well as academic leadership in graduate pharmacy education.

To read Jim’s full bio, click here.


Greg Downing, DO, PhD

Founder of Innovation Horizons, LLC
Greg Downing, DO, PhD

Gregory Downing, D.O., PharmD, Ph.D. is the founder of Innovation Horizons, LLC, a consulting practice with an emphasis on innovation and technology adaptation in health care. Previously, he was the Founding Executive Director for Innovation in the Immediate Office of the Secretary at the United States Department of Health and Human Services (HHS). In this position, his primary responsibilities were focused on the promotion of innovation and entrepreneurship as valued attributes of workforce engagement across HHS. Prior to his arrival at HHS in 2006, Dr. Downing served at the National Institutes of Health since 1993 in research, policy, and program management roles.

To read Greg’s full bio, click here.


Ben Rooks

Managing Principal, ST Advisors, Inc.
Ben Rooks

Ben Rooks is the founder of ST Advisors, a strategic and financial advisory firm focusing on healthcare information technology, IT-enabled services and pure healthcare services firms, as well as their financial sponsors. Prior to founding ST Advisors in 2009, he spent six years as a senior investment banker where he advised healthcare and medical technology companies on transactions ranging from $40 to $365 million. Before investment banking, he spent close to a decade as a sell-side equity research analyst, where he was one of the first analysts to focus on healthcare information stocks as a discrete sector, as well as covering the drug information and pharmacy benefit management sectors.

To read Ben’s full bio, click here.